Neo Comprehensive™ - Heme Cancers
Precise profiling. Expert analysis. Complete results.
Neo Comprehensive – Heme Cancers analyzes genes associated with most hematologic malignancies from myeloid and lymphoid lineages to detect DNA and RNA alterations in one assay:
- 302 genes by DNA sequencing
- 302 genes for SNVs and InDels
- 23 genes for CNVs
- 184 genes by RNA sequencing
- Both known and novel fusion
- Optimized sample usage
- A single total nucleic acid extraction covering both DNA and RNA
- FLT3 by PCR add-on option available*
- Faster FLT3 results for the purpose of therapy selection in cases of new AML diagnoses
Benefits of consolidating all testing at NeoGenomics include:
- Consistency across test reports for easy interpretation of results
- Time-savings in test ordering, shipping, reporting, billing, and more
- Specimen conservation
- Cost-effectiveness
- Access to leading clinical decision support and data services
Resources
Why Comprehensive Genomics Profiling (CGP) in Hematological Malignancies?
CGP use in heme cancers offers both clinical and practical utility, particularly for diagnosis and prognosis, as well as for therapeutic guidance.
CGP optimizes your testing strategy by comprehensively covering all clinically relevant genes, including both diagnostic and prognostic markers and markers that may influence participation in clinical trials.
Additional benefits of CGP in heme cancers include:
- Thoroughness: Use of next generation sequencing (NGS) to complete a hematological cancer(s) workup is highly recommended by latest guidelines
- Diagnosis and Classification: Heme cancers have distinct genomic profiles that may benefit from a CGP to assist in diagnosis and classification without requiring multiple tests
- Therapy Selection: The vast genomic profile of heme cancers benefits from CGP use to support comprehensive identification of potential therapies with sensitivity or resistance
Assay Performance
| Variant Type | Average Sequencing Depth | Sensitivity | Specificity | Reportable Range (20% abnormal cells) |
|---|---|---|---|---|
| SNVs | ≥500X | 98.31% | 99.96% | ≥3% Hotspots, ≥5% all others |
| InDels | ≥500X | 98.85% | 99.99% | ≥3% Hotspots, ≥5% all others |
| CNVs (Gain/Loss) | ≥500X | 95.98% | 98.36% | Gains (≥trisomy) Loss (hetero-/homozygous) |
| Fusions (RNA-seq) | ≥5M reads | 97.01% | 98.20% | 5 reads and AI score |
For a more targeted approach, Neo Comprehensive - Myeloid Disorders is the optimal NGS solution to genomic profiling of myeloid neoplasms.
Neo Comprehensive™ - Myeloid Disorders
The Neo Comprehensive™ - Myeloid Disorders assay analyzes 163 genes to detect DNA and RNA alterations through next-generation sequencing (NGS) as noted below. Test reports include a summary interpretation of all results together.
The Neo Comprehensive - Myeloid Disorders assay detects relevant aberrations for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance. It covers a wide spectrum of myeloid neoplasms, including acute myeloid leukemia (AML); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS); myeloproliferative neoplasms (MPN), e.g., polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET); myeloid neoplasms with eosinophilia and defining gene rearrangement; histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester Disease (ECD); mastocytosis; myeloid precursor lesions.
AML = acute myeloid leukemia; CNVs = copy number variants;
InDels = insertions and deletions; PCR = polymerase chain reaction;
SNVs = single nucleotide variants; WHO = World Health Organization.
* If FLT3 by PCR is added on, it reports separately as soon as completed (approximately 5 days).
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients